Quantitative immunohistochemical fingerprinting of adhesion/growth-regulatory galectins in salivary gland tumors: Divergent profiles with diagnostic potential

Myriam Remmelink, Laurence de Leval, Christine Decaestecker, Anaëlle Duray, Nicolas Sirtaine, Emerence Crompt, Sabine André, Herbert Kaltner, Xavier Leroy, Hans-Joachim Gabius, et al.

► To cite this version:

Myriam Remmelink, Laurence de Leval, Christine Decaestecker, Anaëlle Duray, Nicolas Sirtaine, et al.. Quantitative immunohistochemical fingerprinting of adhesion/growth-regulatory galectins in salivary gland tumors: Divergent profiles with diagnostic potential. *Histopathology*, 2011, 58 (4), pp.543. 10.1111/j.1365-2559.2011.03776.x . hal-00624432

HAL Id: hal-00624432

<https://hal.science/hal-00624432>

Submitted on 17 Sep 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Quantitative immunohistochemical fingerprinting of
adhesion/growth-regulatory galectins in salivary gland
tumors: Divergent profiles with diagnostic potential**

Journal:	<i>Histopathology</i>
Manuscript ID:	HISTOP-12-09-0696.R1
Manuscript Type:	Original Article
Date Submitted by the Author:	21-Apr-2010
Complete List of Authors:	remmelink, myriam de Leval, Laurence; CHU Sart-Tilman, Pathology decaestecker, christine; ULB, toxicology duray, anaëlle; University of Mons, laboratory of anatomy and cellular biology sirtaine, nicolas crompot, emerence andré, sabine kaltner, herbert leroy, xavier Gabius, Hans-Joachim Saussez, Sven; University of Mons-Hainaut, Laboratory of Anatomy
Keywords:	salivary gland, galectin, diagnosis, immunohistochemistry

First of all, as recommended by the associate editor and the reviewer 1 we have reduced the length of the manuscript of about 10%.

Answers to the reviewer 1:

-In the Table 2, we provide a footnote explaining more precisely the data:

“For each type of tissue, the number of cases and the percentage of immunopositive cases relative to the intracellular localization are provided.” We have also clarified the Table 2.

-As recommended, we rewritten the discussion more concisely and add a more elaborate part on the differential diagnostic implications for pathologists:

“The stratification based on intracellular distribution disclosed notable shifts and differences. **For pathologists, this point could be relevant in the histopathological MEC diagnosis because these tumours presented a unique profile based on cytoplasmic localization of Gals-1, -3, -7, and -8 in the intermediate cells.** Here, combination with Gal-7 presence has potential to increase the reliability of subtype diagnosis to separate solid-pattern from tubular/cribriform-patterns malignancies. Moreover, the **absence of Gal-7 expression is also observed in ACC. This could help with distinction from MEC, especially the microcystic variant of ACC. When material is limited, the differential diagnosis between ADCCs and PAs is sometimes challenging. Our study shows that the expression profile of Gals-1, -3, and -7 is different when considering these histopathological specimens. In PA, the absence of nuclear Gal-1 signal and the cytoplasmic and nuclear presence of Gal-3 constitute a characteristic Gal-1, -3 signature, whereas the Gal-3 signal was confined to the cytoplasmic compartment of ADCCs.”**

-As recommended, key messages for pathologists are also add in the abstract:

“Acinic cell and adenoid cystic carcinomas (specifically tubular and cribriform types) shared the expression signature of galectin-1, -3 and -8 presence combined with galectin-7 absence. Mucoepidermoid carcinomas presented a unique profile based on cytoplasmic galectin 1-3-7-8 localization in the intermediate cells.”

-As recommended, we add in the discussion a comment about the utility of galectin immunohistochemistry in routine laboratory:

“-page 13, line 2: **“In summary, our study supports the concept for characteristic signatures of galectin presence when monitoring several proteins of this class, constituting progress in mapping presence of these lectins and indicating potential for differential diagnosis, especially for MEC/ACC.”**

Answers to associate editor:

-As recommended by the associate editor and the reviewer 1, we have reduced the length of the manuscript of about 10% (reduction of more than 300 words).

-In the abstract, we provide a clearly worded sentence on the aims/objectives of our study:

“Aims: Histopathological fingerprinting of galectins, emerging multifunctional effectors in cell sociology, is suggested to refine differential diagnosis. This hypothesis is tested for salivary tumours.”

-As recommended, we provide in the table 1 a list of the histopathological type of tumour.

-In Table 2, 0 is written 0 and not 0%.

Quantitative immunohistochemical fingerprinting of adhesion/growth-regulatory galectins in salivary gland tumours: Divergent profiles with diagnostic potential

Myriam Rommelink, M.D, Ph.D.¹, Laurence de Leval, M.D., Ph.D.², Christine Decaestecker, Ph.D.^{3,*}, Anaëlle Duray⁴, Emerence Crompot⁴, Nicolas Sirtaine, M.D.⁵, Sabine André, Ph.D.⁶, Herbert Kaltner, Vet M.D.⁶, Xavier Leroy, M.D., Ph.D.⁷, Hans-Joachim Gabius, Ph.D.⁶, Sven Saussez, M.D., Ph.D.⁴

¹Department of Pathology, Université Libre de Bruxelles (ULB), Brussels, Belgium.

²Department of Pathology, University of Liège, Liège, Belgium.

³Laboratory of Toxicology, Institute of Pharmacy, ULB, Brussels, Belgium.

⁴Laboratory of Anatomy and Cellular Biology, Faculty of Medicine and Pharmacy, University of Mons, Mons, Belgium.

⁵Department of Pathology, Institut Bordet, ULB, Brussels, Belgium.

⁶Institute of Physiological Chemistry, Faculty of Veterinary Medicine, Ludwig-Maximilians-University Munich, Munich, Germany.

⁷Department of Pathology, Faculty of Medicine, Hôpital Claude Huriez and Centre de Biologie-Pathologie – CHRU, Lille, France.

*LL and CD are Senior Research Associate with the Belgian National Fund for Scientific Research (FNRS, Brussels, Belgium)

Running Title: Galectins in salivary gland cancer

Corresponding author:

S. Saussez, M.D., Ph.D.

Laboratory of Anatomy, Faculty of Medicine and Pharmacy

University of Mons

Pentagone 1B - Avenue du Champ de Mars, 6

B-7000 Mons, Belgium

Tel: 32-65-37 35 56; Fax: 32-65-37 35 57

E-mail: sven.saussez@umons.ac.be

Abstract

Aims: **Histopathological fingerprinting of galectins, emerging multifunctional effectors in cell sociology, is suggested to refine differential diagnosis. This hypothesis is tested for salivary tumours.** *Methods and results:* **We** apply non-cross-reactive polyclonal antibodies against galectins-1, -3, -7, and -8 to immunohistochemical analysis of salivary gland tumours (72 cases with benign disease and 39 cases with malignancy, adding 29 specimens as control). The principal positivity of cases, the site of signal presence and the quantitative parameters concerning percentage of positive cells and labelling intensity were determined. **Acinic cell and adenoid cystic carcinomas (specifically tubular and cribriform types) shared the expression signature of galectin-1, -3 and -8 presence combined with galectin-7 absence. Mucoepidermoid carcinomas presented a unique profile based on cytoplasmic galectin 1-3-7-8 localization in the intermediate cells.** Adenomas were separable from malignancy by a consistent decrease **of the Labeling Index for galectins-7 and -8** (LI Gal-7, $p < 10^{-6}$; LI Gal-8, $p=0.001$). When present, staining for the tumour suppressor p16^{INK4a} coincided with galectin-1 presence. *Conclusions:* Thus, expression profiling of the tested four galectins in salivary gland tumours revealed non-uniform staining patterns with discriminatory potency based on intracellular localization and quantitative aspects.

Key Words: diagnosis, **galectin**, immunohistochemistry, **salivary gland**

Introduction

Proteins serving as multifunctional effectors are promising candidates as markers in histopathology. When gene diversification has led to a family of homologous proteins it is an attractive project line to define individual expression profiles comparatively in tumour material. **Respective studies may reveal new diagnostic tools and insights into clinical correlations.** **Toward this end we focus on** a family of endogenous lectins regulating cell adhesion and growth, i.e. the galectins sharing the β -sandwich fold (1, 2). Systematic RT-PCR screening on tumour cell lines **has revealed that** galectin expression is subject to intricate control (3, 4). **Using** non-crossreactive antibodies presence of **distinct** members of the three subgroups, i.e. proto-type, chimera-type and tandem-repeat-type proteins, in routine tissue sections **can be detected** (5, 6). Thus, questions on relation of **galectins** to malignancy and on contributions to differential diagnosis can hereby be answered.

Previous work on salivary gland tumors has attracted our attention in this respect. Presence of galectins-1 and -3 (Gal-1 and Gal-3) was initially described, further work extending the data basis for Gal-3 with its potential to distinguish polymorphous low-grade adenocarcinoma from adenoid cystic carcinoma (AdCC) remaining controversial (7-11). **Since the** tandem-repeat-type protein Gal-8, is of prognostic relevance in bladder and colon (Dukes C/D) cancer (12, 13), **it was also monitored.** **Proto-type Gal-7 completes our panel of four galectins due to its proven** regulation by the tumour suppressor p53, its effectiveness as growth regulator, and its characteristic distribution different from Gal-1 in laryngeal/hypopharyngeal squamous cell carcinomas (5, 14-18). Since Gal-1 expression is under the control of p16^{INK4a} *in vitro* (19), **detection of** this tumour suppressor protein together with p53 was **performed in serial sections**. In total, we studied material from 111 cases of salivary gland tumours (SGTs), assessing positivity first, then localization and finally quantitative parameter on percentage of stained area and signal intensity. The questions on i) distribution profiles of the four

galectins and their individual characteristics in benign and malignant lesions, ii) differences between tumour types and iii) any relation to the tumour suppressors will be answered.

For Peer Review

Materials and Methods

Patients' Characteristics

A total of 111 tumour cases, comprised of 72 patients with benign SGTs and 39 patients with malignant SGTs who underwent surgery aimed at curative tumour resection, were studied (see Table 1 for clinical data). In 29 specimens of Warthin's tumour, intra- and interlobular ducts in adjacent tumour-free parotid tissue was evaluated. Tumour specimens were obtained by retrospective compilation from the records of the Departments of Pathology of the Hôpital Claude Huriez (XL, Lille, France), the Hôpital Erasme (MR, Brussels, Belgium), the CHU Saint-Pierre-Institut Bordet (NS, Brussels, Belgium) and the CHU Sart-Tilman (LD, Liège, Belgium). The Institutional Review Boards of these hospitals approved the study.

H&E sections of the 111 tumours were examined by two pathologists to confirm the diagnosis and then processed immunohistochemically under identical conditions to semiquantitatively and quantitatively monitor presence of Gals-1, -3, -7 and -8 and the two tested tumour suppressor proteins.

Antibodies

To raise polyclonal antibodies in rabbits, human Gals-1, -3, -7 and -8 were produced in bacteria, purified to homogeneity as ascertained by one- and two-dimensional gel electrophoresis and mass spectrometry and then used as antigens <<<PLEASE INSERT HERE REF 13, 16, 19>>>. The immunoglobulin G fractions resulting from protein A-Sepharose affinity chromatography were rigorously checked for cross-reactivity among this lectin family systematically testing human Gals-1, -2, -3, -4, -7, -8 and -9 in Western blot and ELISA assays, and chromatographic affinity depletion was performed in any case of positivity followed by quality controls to verify complete elimination of cross-reactivity as described previously (20).

Immunohistochemistry

All tumour samples were fixed for 24 h in 10% buffered formaldehyde, dehydrated and routinely embedded in paraffin. Immunohistochemistry was routinely performed on 5 µm-thick sections

mounted on silane-coated glass slides, as detailed recently (5, 21). Before starting the immunohistochemistry protocol, dewaxed tissue sections were briefly subjected to microwave pretreatment in a 0.01 M citrate buffer (pH 6.0) for 2 x 5 min at 900 W. The sections were then incubated with a solution of 0.4% hydrogen peroxide for five min to block endogenous peroxidase activity, rinsed in phosphate-buffered saline (PBS; 0.04 M Na₂HPO₄, 0.01 M KH₂PO₄ and 0.12 M NaCl, pH 7.4) and successively exposed for 20 min to solutions containing avidin (0.1 mg/ml in PBS) and biotin (0.1 mg/ml in PBS) to avoid false-positive staining reactions resulting from endogenous biotin. After a thorough washing with PBS to remove the reagents, the sections were incubated for 20 min with a solution of 0.5 % casein in PBS, again carefully washed and thereafter sequentially exposed at room temperature to solutions of i) the specific primary anti-galectin antibodies; ii) the corresponding biotinylated secondary antibody (polyclonal goat anti-rabbit IgG); and iii) the avidin-biotin-peroxidase complex (ABC kit). Incubation steps were separated by thorough washing steps to remove any unbound proteins. Antigen-dependent presence of the peroxidase complex in the sections was visualized by incubation with solution containing the chromogenic substrates diaminobenzidine and H₂O₂. After rinsing, the sections were counterstained with luxol fast blue and mounted with a synthetic medium. To exclude antigen-independent staining, the incubation step with primary/secondary antibodies was omitted from the protocol in controls. In all cases these controls were negative. The biotinylated secondary antibodies and the ABC kit came from DakoCytomation (Glostrup, Denmark), antibodies against the tumour suppressors p16^{INK4a} from Abcam (Cambridge, UK) and p53 from DakoCytomation.

Semi-quantitative analysis

For each specimen (15 microscopic fields), the intensity of the immunostaining (Mean Intensity, MI) was scored as 0 (negative), 1 (weak), 2 (moderate) or 3 (strong), and its presence (Labelling Index, LI) was graded into categories of percentage of positive cells as 0 (0% positive cells), 1 (1-25%), 2 (>25%)

and < 75%) or 3 (>75% up to 100%). The quick score (QS) was calculated by multiplying the score of intensity of reactivity with the category of the percentage of immunopositive cells.

Quantitative analysis using computer-assisted microscopy

Following the immunohistochemical processing steps, the quantitative aspects of signal intensity and distribution were determined using a computer-assisted KS 400 imaging system (Carl Zeiss Vision, Hallbergmoos, Germany) connected to a Zeiss Axioplan microscope, as detailed previously (17). For each microscopic field, we focused analysis on the tumoural region using computer-assisted morphometry after interactive identification. In each case, we scanned 15 fields covering a surface area ranging from 60,000 to 120,000 μm^2 . In each case, the quantitative analysis of immunohistochemical staining for a given marker yielded data on two variables: 1) the Labelling Index (LI), i.e. the percentage of positive cells, and 2) the Mean Optical Density (MOD), i.e. staining intensity of positive cells (17). For each case of SGTs, the respective fields were defined by one of us (MR, XL, LD, NS) specialised in this diagnostic procedure.

Data analysis

Independent groups of quantitative data were compared using the non-parametric Kruskal-Wallis (more than two groups). In the case of more than two groups, post-hoc tests (Dunn procedure) were used to compare pairs of groups (to avoid multiple comparison effects). The statistical analyses were carried out using Statistica software (Statsoft, Tulsa, USA).

Results

Our study started with comparative analysis of the staining profiles of the four antibody preparations in 29 control cases, examining the adjacent tumour-free tissue in sections of Warthin's tumour. Whereas acini were generally negative, a clear difference was seen between Gal-1, here lymphoid cells serving as positive controls (Fig. 1A, B), and the other three types of galectins (Fig. 1A-F). The profiles of **Gal-7** immunopositivity in intra- and interlobular ducts were remarkably comparable. Both types of duct (intra- and interlobular) presented very strong cytoplasmic and nuclear immunostaining of the basal layer and moderate cytoplasmic expression in the luminal layer (Fig. 1E, F). Of particular note, nucleocytoplasmic presence was detected in inter- and intralobular ducts consistently for Gals-1, -3 and -7 (Fig. 1A-F). In contrast, Gal-8 was exclusively cytoplasmic (Fig. 1G, H; Table 2).

Moving on to benign lesions, these cases were first classified. 44 out of the 72 cases (66%) of pleomorphic adenoma (PA) presented both epithelial and chondroid compartments. These two components are **shown** separately in Fig. 2A-H, revealing moderate to strong nucleocytoplasmic positivity for Gal-1 in 73% or 75% of the cases, respectively (Fig. 2A, E; Table 2). Gal-3 presence was detected in 68% of the cases with epithelial component, showing either cytoplasmic (59%) or also nucleocytoplasmic positivity (44%) (Fig. 2B; Table 2). Also, the chondroid component was **positive for** Gal-3 in 50% of the cases with similar intracellular distribution (Fig. 2F). While the epithelial part harboured Gal-7 in 60% of the cases with nucleocytoplasmic localization, only 33% presented a signal for the chondroid part (Fig. 2C, G; Table 2). In contrast, Gal-8 expression was abundant in 90% and 82% in these two components, with staining seen both in the cytoplasm and in nuclei (Fig. 2D,H; Table 2). PA formation is apparently associated with a shift of Gal-3 from nuclear also to cytoplasmic sites and of Gal-8 from exclusively cytoplasmic also to nuclear sites, maintaining the

cytoplasmic presence (Table 2). Regarding frequency, there appears to be a graded occurrence instead of uniform expression with a ranking from Gal-8, then to Gal-1, -3 and -7 in terms of positivity by cases.

Analysis of the adenoid cystic carcinomas (AdCC; total of 15 cases) was subdivided into cases with solid (eight patients), cribriform (five patients) and tubular patterns (two patients). Gal-1 was invariably present in tumour cells, detected both in nuclei and in cytoplasm (66%) or exclusively in nuclei (markedly for cribriform types, not at all for solid-pattern-type tumours) and in stroma (Fig. 3A-C; Table 2). All eight cases with the solid pattern showed nucleocytoplasmic presence (Table 2). In contrast to Gal-1, peritumoral cells were consistently negative for Gal-3, while 13 from 15 cases yielded cytoplasmic signals of weak to moderate intensity (Fig. 3D-F; Table 2). No nuclear signals were seen. In terms of subtype selectivity no immunopositivity for Gal-7 was detected in tubular tumors, only one cribriform tumour was positive, solid ones revealing strong nucleocytoplasmic signals in four of eight cases (Fig 3G-I; Table 2). As described already for Gals-1 and -3 in terms of occurrence, the tandem-repeat-type **Gal-8** was present in most cases (14 from 15 cases), invariably localized in the cytoplasm, with added nuclear presence in three cases of the cribriform and solid types (Fig. 3J-L; Table 2).

In muco-epidermoid carcinomas (MEC; six cases) intermediate cells were always positive for Gal-1, mucus cell invariably negative (Fig. 4A). Overall, except for one case with Gal-8 positivity, staining was consistently cytoplasmic (Table 2). Intertumoral heterogeneity was observed for Gals-3 and -7, with positivity restricted to intermediate cells in three cases (Fig. 4B, C). Immunolabelling for **Gal-8** was observed cytoplasmically in both cell types in five from six cases (Fig. 4D; Table 2).

Acinic cell carcinomas (ACC; nine cases) were generally positive for Gal-1 in the intercalated duct-type cells (Fig. 5A). This nucleocytoplasmic staining pattern contrasted with

exclusively cytoplasmic positivity for Gal-3 in three of nine cases (Fig. 5B) and even complete lack of positivity for Gal-7 (Fig. 5C; Table 2). Gal-8, however, shared staining properties with Gal-1 in signal intensity and site of staining, four cases also presenting nuclear positivity (Fig. 5D; Table 2). This distribution is in conspicuous contrast to the profile of galectin presence in carcinoma ex pleomorphic adenomas (CA-ex-PA) with immunopositivity for Gals-1, -3 and -8 in all cases (Fig. 6A,B,D) and for Gal-7 in five of nine cases (Fig. 6C). Staining was invariably nucleocytoplasmic for Gal-1 and -7, in eight of nine cases exclusively cytoplasmic for Gal-8 (Table 2). Combining signal presence and localization adds up to a distinct signature. Among the 39 cases with malignancy, p53 was detectable in four cases (two ACCs, two CA-ex-PAs), of which one CA-ex-PA was strongly immunopositive for Gal-7. Weak p16^{INK4a}-dependent signals were picked up in six cases (four AdCCs, two CA-ex-PA), always associated with Gal-1 presence.

Analyzing the quantitative data for each galectin with respect to the different tumour types (Fig. 7), an increase for Gal-1 pertains to the percentage of positive cells (LI parameter; Kruskal-Wallis: $p=0.001$). A highly significant difference (post-hoc comparison; $p = 0.0006$) concerned the labelling index between the chondroid component in PAs and the CA-ex-PAs (Fig. 7B). These two correlations also showed up in the case of Gal-3, albeit with reduced level of statistical significance at $p=0.01$ and $p=0.004$, respectively (Fig. 7D). In contrast, presence of Gals-7 and -8 was subject to downregulation. Prominent differences in this respect led to a separation in two groups constituted by PA and the corresponding carcinoma vs the other three studied types of malignancy for Gal-7 in both categories of quantitative data (MOD, LI; Kruskal-Wallis: $p < 10^{-6}$) (Fig. 8A, B). Post-hoc comparisons between the CA-ex-PAs and AdCCs yielded p-values at 0.03 for the MOD parameter and at 0.01 for the LI variable. As shown in Fig. 8A, B, the epithelial component in PA showed strikingly stronger signal presence than cases with malignancy (also p-value for comparison to MECs at 0.01 for

MOD variable). The chondroid component, too, differed from adenoid cystic and acinic cell carcinomas. Concerning Gal-8, malignancies – except for the MECs – were associated with a decrease in signal (Fig. 8C, D). As documented in Fig. 8C, the groups of CA-ex-PAs and pleomorphic adenoma (epithelial component) were separated at $p = 0.03$ in post-hoc comparison. The difference between epithelial component of adenoma and AdCC reached significance for both quantitative parameters ($p = 0.049$ for the labelling index, here also for ACCs (Fig. 8C, D)). The p-value between the chondroid component and ACCs was at 0.02. Thus, while percentage of labelled cells for Gals-1 and -3 increased in CA-ex-PA, a decrease was noted for Gal-7 (excluding the CA-ex-PAs) and for Gal-8 (excluding MECs).

Discussion

Galectins are capable to turn presence of distinct glycans into cellular responses, e.g. in growth control of tumour cells (16, 19, 22-25). In addition, they are also known to be present within the cell, and act in concert with distinct target proteins such as oncogenic H-ras or effectors in the apoptotic or splicing cascades (2, 26-28). As case studies for salivary gland tumours **have documented** (7-11), the investigation of this lectin group has so far mainly been focused on Gals-1 and -3. Analysis of further family members, at best by fingerprinting studies, is at a rather early stage. Emerging data from head and neck tumours underscore its pertinence, i.e. by revealing association of presence of Gals-1 and -7 with progression to malignancy and inverse shifts between nuclear and cytoplasmic localization in laryngeal/hypopharyngeal squamous cell carcinomas as well as the upregulation of Gal-8 in these tumours in contrast to an often encountered downregulation in other tumour types, hereby strongly indicating intriguing divergence between different galectins (17, 29, 30). In order to pursue these indications, a promising methodological approach **exemplified in this study** is a.) monitoring presence of galectins from the three subgroups in parallel

immunohistochemically, b.) determining their localization profiles and c.) assessing staining parameters quantitatively.

This study examines proto-type (Gal-1/-7), chimera-type (Gal-3) and tandem-repeat-type (Gal-8) galectins comparatively. It teaches several key lessons, starting with detection of a definitely non-uniform regulation of the individual, closely related proteins. The patterns of presence in PA with grading from Gal-8 to Gal-1, Gal-3 and finally Gal-7 illustrates this point. Of note, specimens of Warthin's tumour were consistently negative for Gal-1, while maintaining features for Gals-3, -7, and -8 (31). As internal standard for validity of inter-study comparison our data are in accord with high degree of positivity of Gal-3 in AdCCs (7-11). The stratification based on intracellular distribution disclosed notable shifts and differences.

For pathologists, this point could be relevant in the histopathological MEC diagnosis because these tumours presented a unique profile based on cytoplasmic localization of Gals-1, -3, -7, and -8 in the intermediate cells. Here, combination with Gal-7 presence has potential to increase the reliability of subtype diagnosis to separate solid-pattern from tubular/cribriform-patterns malignancies. Moreover, the **absence of Gal-7 expression is also observed in ACC. This could help with distinction from MEC, especially the microcystic variant of ACC. When material is limited, the differential diagnosis between ADCCs and PAs is sometimes challenging. Our study shows that the expression profile of Gals-1, -3, and -7 is different when considering these histopathological specimens. In PA, the absence of nuclear Gal-1 signal and the cytoplasmic and nuclear presence of Gal-3 constitute a characteristic Gal-1, -3 signature, whereas the Gal-3 signal was confined to the cytoplasmic compartment of ADCCs.** Between CA-ex-PA and MEC/ACC/AdCC the signature of nucleocytoplasmic Gals-1/-3/-7 and cytoplasmic Gal-8 is rather specific, underscoring the potential of fingerprinting combined with staining-site monitoring. When **positive** (in six from 39 tumour cases), presence of the tumour suppressor p16^{INK4a} was

associated with Gal-1 presence, in line with a role of this protein **to enhance Gal-1 gene transcription** (19). **In summary, our study supports the concept for characteristic signatures of galectin presence when monitoring several proteins of this class, constituting progress in mapping presence of these lectins and indicating potential for differential diagnosis, especially for MEC/ACC.**

References:

1. Cooper DNW. Galectinomics: finding themes in complexity. *Biochim Biophys Acta* 2002;1572;209-231.
2. Schwartz-Albiez R. Inflammation and glycosciences. In: *The Sugar Code. Fundamentals of glycosciences* (Ed. Gabius H-J), pp. 447-467. Wiley-VCH, Weinheim, Germany, 2009.
3. Gabius H-J, Brehler R, Schauer A, Cramer F. Localization of endogenous lectins in normal human breast, benign breast lesions and mammary carcinomas. *Virch Arch [Cell Pathol]* 1986;52;107-115.
4. Lahm H, André S, Hoeflich A *et al.* Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. *J Cancer Res Clin Oncol* 2001;127;375-386.
5. Saussez S, Cucu DR, Decaestecker C *et al.* Galectin-7 (p53-induced gene-1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. *Ann Surg Oncol* 2006;13;999-1009.
6. Cada Z, Smetana K Jr, Lacina L *et al.* Immunohistochemical fingerprinting of the network of seven adhesion/growth-regulatory lectins in human skin and detection of distinct tumor-associated alterations. *Folia Biol* 2009;55;145-152.
7. Xu XC, Sola Gallego JJ, Lotan R, El-Naggar AK. Differential expression of galectin-1 and galectin-3 in benign and malignant salivary gland neoplasms. *Int J Oncol* 2000;17;271-276.
8. Penner CR, Folpe AL, Budnick SD. C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. *Mod Pathol* 2002;15;687-691.
9. Teymoortash A, Pientka A, Schrader C, Tiemann M, Werner JA. Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis. *J Cancer Res Clin Oncol* 2006;132;51-56.

10. Ferrazzo KL, Alves SM Jr, Santos E, Martins MT, de Sousa SM. Galectin-3 immunoprofile in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands. *Oral Oncol* 2007;43;580-585.
11. Ferrazzo KL, Neto MM, dos Santos E, dos Santos Pinto D, de Sousa SO. Differential expression of galectin-3, β -catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands. *J Oral Pathol Med*:in press.
12. Nagy N, Legendre H, Engels O *et al*. Refined prognostic evaluation in colon cancer using immunohistochemical galectin fingerprinting. *Cancer* 2003;97;1849-1858.
13. Langbein S, Brade J, Badawi JK *et al*. Gene-expression signature of adhesion/growth-regulatory tissue lectins (galectins) in transitional cell cancer and its prognostic relevance. *Histopathology* 2007;51;681-690.
14. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. *Nature* 1997;389;300-305.
15. Bernerd F, Sarasin A, Magnaldo T. Galectin-7 overexpression is associated with the apoptotic process in UVB-induced sunburn keratinocytes. *Proc Natl Acad Sci USA* 1999;96;11329-11334.
16. Kopitz J, André S, von Reitzenstein C *et al*. Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells. *Oncogene* 2003;22;6277-6288.
17. Saussez S, Decaestecker C, Lorfevre F *et al*. Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and -7 during tumour progression in hypopharyngeal and laryngeal squamous cell carcinomas. *Histopathology* 2008;52;483-493.
18. Cada Z, Chovanec M, Smetana K *et al*. Galectin-7: will the lectin's activity establish clinical correlations in head and neck squamous cell and basal cell carcinomas? *Histol Histopathol* 2009;24;41-48.
19. André S, Sanchez-Ruderisch H, Nakagawa H *et al*. Tumor suppressor p16^{INK4a}: modulator of glycomic profile and galectin-1 expression to increase susceptibility to carbohydrate-dependent induction of anoikis in pancreatic carcinoma cells. *FEBS J* 2007;274;3233-3256.
20. Lohr M, Kaltner H, Lensch M, André S, Sinowatz F, Gabius HJ. Cell-type-specific expression of murine multifunctional galectin-3 and its association with follicular atresia/luteolysis in contrast to pro-apoptotic galectins-1 and -7. *Histochem Cell Biol* 2008;130;567-581.

21. Saussez S, Decaestecker C, Mahillon V *et al.* Galectin-3 upregulation during tumor progression in head and neck cancer. *Laryngoscope* 2008;118;1583-1590.
22. Kopitz J, von Reitzenstein C, André S, *et al.* Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. *J Biol Chem.* 2001;276:35917-35923.
23. Fischer C, Sanchez-Ruderisch H, Welzel M, *et al.* Galectin-1 interacts with the $\alpha_5\beta_1$ fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. *J Biol Chem.* 2005;280:37266-37277.
24. Patsos G, André S, Roeckel N *et al.* Compensation of loss of protein function in microsatellite-unstable colon cancer cells (HCT116): a gene-dependent effect on the cell surface glycan profile. *Glycobiology* 2009;19;726-734.
25. Gabius H-J, ed. The Sugar Code. Fundamentals of glycosciences. Weinheim, Germany: Wiley-VCH; 2009.
26. Rotblat B, Niv H, André S, Kaltner H, Gabius HJ, Kloog Y. Galectin-1(L11A) predicted from a computed galectin-1 farnesyl-binding pocket selectively inhibits Ras-GTP. *Cancer Res* 2004;64;3112-3118.
27. Wang JL, Gray RM, Haudek KC, Patterson RJ. Nucleocytoplasmic lectins. *Biochim Biophys Acta* 2004;1673;75-93.
28. Smetana K Jr, Dvoránková B, Chovanec M *et al.* Nuclear presence of adhesion/growth-regulatory galectins in normal/malignant cells of squamous epithelial origin. *Histochem Cell Biol* 2006;125;171-182.
29. Danguy A, Rorive S, Decaestecker C *et al.* Immunohistochemical profile of galectin-8 expression in benign and malignant tumors of epithelial, mesenchymatous and adipous origins, and of the nervous system. *Histol Histopathol* 2001;16;861-868.
30. Cludts S, Decaestecker C, Mahillon V *et al.* Galectin-8 upregulation during hypopharyngeal and laryngeal tumor progression and comparison with galectins-1, -3, and -7. *Anticancer Res* 2009;29:4933-4940.
31. Saussez S, de Leval L, Decaestecker C *et al.* Galectin fingerprinting in Warthin's tumors: lectin-based approach to trace its origin? *Histol Histopathol* 2010;25:541-550.

Legends to Figures

Figure 1: Immunohistochemical staining profiles for galectins-1, -3, -7 and -8 in intralobular (A, C, E, G), and in interlobular ducts (B, D, F, H). Magnification A-H x 320.

Figure 2: Immunohistochemical staining profiles for galectins-1, -3, -7, and -8 in epithelial (A-D) and in chondroid compartments (E-H) of PA. Magnification A-H x 320.

Figure 3: Immunohistochemical staining profiles for galectins-1, -3, -7, and -8 in solid (A, D, G, J), cribriform (B, E, H, K), and in tubular (C, F, I, L) AdCCs. Magnification A-H x 320.

Figure 4: Immunohistochemical staining profiles for galectins-1, -3, -7, and -8 in MEC (A-D). Magnification A-H x 320.

Figure 5: Immunohistochemical staining profiles for galectins-1, -3, -7, and -8 in ACC (A-D). Magnification A-H x 320.

Figure 6: Immunohistochemical staining profiles for galectins-1, -3, -7, and -8 in CA-ex-PA (A-D). Magnification A-H x 320.

Figure 7: Quantitative determination (by computer-assisted microscopy) of the percentages of cells immunopositive for galectins-1 or -3 (the Labelling Index, LI) (B, D) and the respective staining intensity (the Mean Optical Density, MOD) (A, C) in a series of 34 PA (20 cases of e-PA and 15 cases of c-PA), nine Ca-ex-PA, six MEC, 15 AdCC and nine ACC. *Post-hoc* comparisons were used to compare pairs of groups indicated by the arrow.

Figure 8: Quantitative determination (by computer-assisted microscopy) of the percentages of cells immunopositive for galectins-7 or -8 (the Labelling Index, LI) (B, D) and the respective staining intensity (the Mean Optical Density, MOD) (A, C) in a series of 34 PA (20 cases of e-PA and 15 cases of c-PA), 9 Ca-ex-PA, 6 MEC, 15 AdCC and 9 ACC. *Post-hoc* comparisons were used to compare pairs of groups indicated by the arrow.

Table 1: **Clinical data**

Benign Salivary Gland Tumors
<p>-Sex : 38 females/34males</p> <p>-Age: 46.3 years (range between 14 and 77 years)</p> <p>-Localization: 72 parotid tumors</p> <p>-Treatment: 72 superficial parotidectomies.</p> <p>-Histology: 72 cases of pleomorphic adenoma</p>
Malignant Salivary Gland Tumors
<p>-Sex: 22 females/ 17 males</p> <p>-Age: 52.4 years (range between 19 and 88 years)</p> <p>-Localization: 3 sub-mandibular specimens 7 oral cavity specimens 29 parotid specimens</p> <p>-Treatment: 23 superficial parotidectomies 6 total parotidectomies 7 neck dissections 10 local (oral cavity or submandibular) resections.</p> <p>-Histology: 15 cases of adenoid cystic carcinoma 9 cases of mucoepidermoid carcinoma 9 cases of carcinoma ex-pleomorphic adenoma 6 cases of acinic cell carcinoma.</p>

Table 2: Intracellular localization of galectins-1, -3, -7 and -8^a

Type of tissue	Galectin-1			Galectin-3			Galectin-7			Galectin-8		
	Localization			Localization			Localization			Localization		
	C	N	C+N	C	N	C+N	C	N	C+N	C	N	C+N
Intralobular ducts	0	0	25 (100%)	0	0	25(100%)	0	0	14 (100%)	28 (100%)	0	0 (0%)
Interlobular ducts	0	0	22 (100%)	0	0	25 (100%)	0	0	14 (100%)	28 (100%)	0	0 (0%)
Pleomorphic adenoma: epithelial component	0	0	52 (100%)	29 (59%)	0	20 (41%)	2 (5%)	3 (7%)	38 (88%)	1 (2%)	0	64 (98%)
chondroid component	0	0	33 (100%)	10 (43%)	0	13 (57%)	0	2 (13%)	14 (87%)	0	0	36 (100%)
Adenoid cystic carcinoma:												
Tubular type	0	2(100%)	0 (0%)	2 (100%)	0	0 (0%)	0	0	0	1 (100%)	0	0
cribriform type	0	3(60%)	2 (40%)	5 (100%)	0	0 (0%)	0	0	1 (100%)	2 (40%)	0	3 (60%)
solid type	0	0	8 (100%)	6 (100%)	0	0 (0%)	0	0	4 (100%)	5 (63%)	0	3 (37%)
Mucoepidermoid carcinoma	6(100%)	0	0	3 (100%)	0	0 (0%)	3 (100%)	0	0	5 (83%)	0	1 (17%)
Acinic cell carcinoma	0	0	9 (100%)	3 (100%)	0	0 (0%)	0	0	0	5 (56%)	0	4 (44%)
Carcinoma ex pleomorphic adenoma	0	0	9 (100%)	4 (44%)	0	5 (56%)	0	0	5 (100%)	8 (89%)	0	1 (11%)

^a separated into presence of signal in cytoplasm (C) and/or nuclei (N). **For each type of tissue, the number of cases and the percentage of immunopositive cases relative to the intracellular localization are provided.**

figure 1
190x254mm (96 x 96 DPI)

figure 2
190x254mm (96 x 96 DPI)

figure 3
190x254mm (96 x 96 DPI)

figure 4
254x190mm (96 x 96 DPI)

figure 5
254x190mm (96 x 96 DPI)

figure 6
254x190mm (96 x 96 DPI)

254x190mm (96 x 96 DPI)

figure 8
254x190mm (96 x 96 DPI)